Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Cited by (548)

Items 101–200 of 548

1. Bcl-XL: A multifunctional anti-apoptotic protein
   Mingxue Li, Dun Wang, Jianhua He, Lixia Chen, Hua Li · 2019 · Pharmacological Research
2. Regulation of platelet lifespan by apoptosis
   Marion Lebois, Emma C. Josefsson · 2016 · Platelets
3. Acid ceramidase is upregulated in AML and represents a novel therapeutic target
   Su‐Fern Tan, Xin Liu, Todd E. Fox, Brian M. Barth, Arati K. Sharma, Stephen Turner, Andy Awwad, Alden Dewey, Kenichiro Doi, Barbara G. Spitzer et al. · 2016 · Oncotarget
4. BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
   Christopher James Gibson, Matthew Steven Davids · 2015 · Clinical Cancer Research
5. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells
   Sara Ayatollahi, Zahra Salmasi, Maryam Hashemi, Saeedeh Askarian, Reza Kazemi Oskuee, Khalil Abnous, Mohammad Ramezani · 2017 · The International Journal of Biochemistry & Cell Biology
6. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
   Song, Kyung-A, Niederst, Matthew J., Lochmann, Timothy L., Hata, Aaron N., Kitai, Hidenori, Ham, Jungoh, Floros, Konstantinos V., Hicks, Mark A., Hu, Haichuan, Mulvey, Hillary E. et al. · 2018 · Clinical Cancer Research
7. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition
   Clare E. Weeden, Casey Ah-Cann, Aliaksei Z. Holik, Julie Pasquet, Jean-Marc Garnier, Delphine Mérino, Guillaume Lessène, Marie-Liesse Asselin-Labat · 2018 · Oncogene
8. Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer
   Stephanie Berger, Erik Procko, Daciana H. Margineantu, Erinna F. Lee, Betty W. Shen, Alex Zelter, Daniel‐Adriano Silva, Kusum Chawla, Marco J. Herold, Jean-Marc Garnier et al. · 2016 · eLife
9. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer
   Nangia, Varuna, Siddiqui, Faria M., Caenepeel, Sean, Timonina, Daria, Bilton, Samantha J., Phan, Nicole, Gomez-Caraballo, Maria, Archibald, Hannah L., Li, Chendi, Fraser, Cameron et al. · 2018 · Cancer Discovery
10. Targeting the tumor microenvironment in chronic lymphocytic leukemia
    Rebecka Svanberg, Sine Janum, Piers Patten, Alan G. Ramsay, Carsten Utoft Niemann · 2021 · Haematologica
11. BH3-dependent and independent activation of BAX and BAK in mitochondrial apoptosis
    Paul Jeng, Akane Inoue‐Yamauchi, James J.-D. Hsieh, Emily H. Y. Cheng · 2018 · Current Opinion in Physiology
12. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment
    Bagher Farhood, Nasser Hashemi Goradel, Keywan Mortezaee, Neda Khanlarkhani, Masoud Najafi, Amirhossein Sahebkar · 2018 · Journal of Cellular Physiology
13. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution
    Ana C. Henriques, Diana Roberta Ribeiro, Joel Pedrosa, Bruno Filipe Carmelino Cardoso Sarmento, Patrícia M. A. Silva, Hassan Bousbaa · 2018 · Cancer Letters
14. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
    Anne Slomp, Laura M Moesbergen, Jianan Gong, Marta Cuenca, Peter A. von dem Borne, Pieter Sonneveld, David C.S. Huang, Monique C. Minnema, Victor Peperzak · 2019 · Blood Advances
15. The redox-senescence axis and its therapeutic targeting
    Natalie Y.L. Ngoi, Angeline Qiu Xia Liew, Stephen Jun Fei Chong, Matthew Steven Davids, Marie‐Véronique Clement, Shazib Pervaiz · 2021 · Redox Biology
16. The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype
    Yohannes Afework Mebratu, Sourabh Soni, Lorena Rosas, Mauricio M. Rojas, Jeffrey Craig Horowitz, Richard Seonghun Nho · 2023 · American Journal of Physiology-Cell Physiology
17. BH3-only protein BIM: An emerging target in chemotherapy
    Shatrunajay Shukla, Sugandh Saxena, Brijesh Kumar Singh, Poonam Kakkar · 2017 · European Journal of Cell Biology
18. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2
    Nathan P. Coussens, Stephen C. Kales, Mark J. Henderson, Olivia W. Lee, Kurumi Y. Horiuchi, Yuren Wang, Qing Chen, Ekaterina Kuznetsova, Jianghong Wu, Sirisha Chakka et al. · 2018 · Journal of Biological Chemistry
19. The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game
    Yifan Zhan, Andrew M. Lew, Michaël Chopin · 2019 · Frontiers in Immunology
20. Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
    Yunxiong Wei, Yaqing Cao, Rui Sun, Lin Cheng, Xia Xiong, Xin Kinson Jin, Xiaoyuan He, Wenyi Lu, Mingfeng Zhao · 2020 · Frontiers in Oncology
21. Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatment
    Meike Vogler, Harriet S. Walter, Martin J.S. Dyer · 2017 · British Journal of Haematology
22. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
    Bora Lim, Yoshimi Endo Greer, Stanley Lipkowitz, Naoko Takebe · 2019 · Cancers
23. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL
    Chun‐wa Chung, Han Dai, Esther Fernández, Christopher P. Tinworth, Ian Churcher, Jenni Cryan, Jane C. Denyer, John D. Harling, Agnieszka Konopacka, Markus A. Queisser et al. · 2020 · ACS Chemical Biology
24. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
    Piers A. Blombery, Thomas Eliot Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka M. Handunnetti, Dennis A. Carney et al. · 2021 · Blood
25. Regulation of Apoptosis during Flavivirus Infection
    Toru Okamoto, Tatsuya Suzuki, Shinji Kusakabe, Makoto Tokunaga, Junki Hirano, Yuka Miyata, Yoshiharu Matsuura · 2017 · Viruses
26. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer
    Kevin Lin, Justine C. Rutter, Abigail Xie, Bryann Pardieu, Emily T. Winn, Reinaldo Dal Bello, Antoine Forget, Raphaël Itzykson, Yeong-Ran Ahn, Ziwei Dai et al. · 2020 · Nature Genetics
27. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X _L
    Zhang, Xuan, Thummuri, Dinesh, He, Yonghan, Liu, Xingui, Zhang, Peiyi, Zhou, Daohong, Zheng, Guangrong · 2019 · Chemical Communications
28. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances
    Huanling Wu, Leonard Jeffrey Medeiros, Ken H. Young · 2017 · Blood Reviews
29. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
    Patricia Gomez‐Bougie, Sophie Maïga, Benoît Tessoulin, Jessie Bourcier, Antoine Bonnet, Manuel S. Rodríguez, Steven Le Gouill, Cyrille Touzeau, Philippe Moreau, Catherine Pellat‐Deceunynck et al. · 2018 · Blood
30. Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer
    Lloyd Mabonga, Abidemi Paul Kappo · 2019 · International Journal of Peptide Research and Therapeutics
31. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
    Darren C. Phillips, Sha S Jin, Gareth Peter Gregory, Qi Zhang, John Xue, Xiaoxian Zhao, Jun Chen, Yunsong Tong, Haichao Zhang, Morey L. Smith et al. · 2019 · Leukemia
32. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses
    Georg Karpel‐Massler, Chiaki Tsuge Ishida, Elena Bianchetti, Chang Shu, Rolando Pérez‐Lorenzo, Basil A. J. Horst, Matei A. Banu, Kevin Aaron Roth, Jeffrey N. Bruce, Peter Canoll et al. · 2017 · Cancer Research
33. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
    Mariana Villalobos-Ortiz, Jeremy A. Ryan, Thelma Mashaka, Joseph T. Opferman, Anthony G. Letai · 2019 · Cell Death and Differentiation
34. Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
    Vicente J. Fresquet, Maria Jose Garcia-Barchino, Marta Larráyoz, Jon Celay, Carmen Vicente, Marta Fernández‐Galilea, María José Larráyoz, Marı́a José Calasanz, Carlos Panizo, Alexandra Junza et al. · 2020 · Cancer Discovery
35. Aging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis
    Xinxin Zhang, Shi‐Hao He, Xu Liang, Wei Li, Tian-Fang Li, Daifeng Li · 2021 · Frontiers in Pharmacology
36. Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis
    Mary Speir, Kate E. Lawlor, Stefan P. Glaser, Gilu Abraham, Seong Hoong Chow, Adam J. Vogrin, Keith E. Schulze, Ralf Schuelein, Lorraine Ann O’Reilly, Kylie D. Mason et al. · 2016 · Nature Microbiology
37. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
    Nabanita Mukherjee, Jenette Skees, Kaleb J. Todd, Drake A. West, Karoline A. Lambert, William Allen Robinson, Carol M. Amato, Kasey L. Couts, Robert J. Van Gulick, Morgan L. MacBeth et al. · 2020 · Cell Death and Disease
38. Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer
    Natalie Y.L. Ngoi, Clarice Shi Hui Choong, Joanne Lee, Gregory Lucien Bellot, Andrea L.A. Wong, Boon Cher Goh, Shazib Pervaiz · 2020 · Cancers
39. Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
    Joan Montero, Rizwan Haq · 2022 · Cancer Discovery
40. Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
    Anna Tutusaus, Milica Stefanović, Loreto Boix, Blanca Cucarull, A. González Zamora, Laura Blasco, Pablo Garcı́a de Frutos, María Reig, José Carlos Fernández-Checa, Montserrat Marı́ et al. · 2018 · Oncotarget
41. Selective targeting of antiapoptotic BCL‐2 proteins in cancer
    Ahmet Can Timuçin, Hüveyda Başağa, Özgür Kütük · 2018 · Medicinal Research Reviews
42. Adenoid cystic carcinoma: emerging role of translocations and gene fusions
    Piotr Wysocki, Evgeny Izumchenko, Juliet Meir, Patrick K. Ha, David Sidransky, Mariana Brait · 2016 · Oncotarget
43. BCL-2: Long and winding path from discovery to therapeutic target
    Robyn L. Schenk, Andreas Strasser, Grant Dewson · 2017 · Biochemical and Biophysical Research Communications
44. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia
    Andrew Warwick Roberts, Stephan Stilgenbauer, John Francis Seymour, David C.S. Huang · 2017 · Clinical Cancer Research
45. It's time to die: BH3 mimetics in solid tumors
    Sarah Kehr, Meike Vogler · 2021 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
46. Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases
    Josefsson, Emma C., Vainchenker, William, James, Chloe · 2020 · International Journal of Molecular Sciences
47. Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
    Arvind Negi, Anne Sophie Voisin‐Chiret · 2022 · ChemBioChem
48. KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells
    Zhichuan Zhu, Jiwei Liu, Kui Li, Jing Zheng, Zhi‐Qi Xiong · 2018 · Oncogene
49. Cell death pathologies: targeting death pathways and the immune system for cancer therapy
    Francesca Pentimalli, Sandro Grelli, Nicola Di Daniele, Gerry Melino, Ivano Amelio · 2018 · Genes and Immunity
50. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors
    Lloyd T. Lam, Xiaoyu Lin, Emily J. Faivre, Ziping Yang, Xiaoli Huang, Denise M. Wilcox, Richard J. Bellin, Sha S Jin, Stephen K. Tahir, Michael J. Mitten et al. · 2017 · Molecular Cancer Therapeutics
51. Recent Applications of Pd-Catalyzed Suzuki–Miyaura and Buchwald–Hartwig Couplings in Pharmaceutical Process Chemistry
    Balaram S. Takale, Fanyi Kong, Ruchita Rajendra Thakore · 2022 · Organics
52. Metformin mitigates SASP secretion and LPS-triggered hyper-inflammation in Doxorubicin-induced senescent endothelial cells
    Ibrahim Y. Abdelgawad, Kevin J. Agostinucci, Bushra Sadaf, Marianne K. O. Grant, Beshay N. M. Zordoky · 2023 · Frontiers in Aging
53. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response
    Ioannis K. Zervantonakis, Claudia Iavarone, Hsing‐Yu Chen, Laura M. Selfors, Sangeetha S. Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Joel D. Leverson, Deepak Sampath et al. · 2017 · Nature Communications
54. Bok is a genuine multi-BH-domain protein that triggers apoptosis in the absence of Bax and Bak
    Einsele-Scholz, Stephanie, Malmsheimer, Silke, Bertram, Katrin, Stehle, Daniel, Johänning, Janina, Manz, Marianne, Daniel, Peter T., Gillissen, Bernhard F., Schulze-Osthoff, Klaus, Essmann, Frank · 2016 · Journal of Cell Science
55. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf ^−/− mouse model
    Chapeau, Emilie A., Gembarska, Agnieszka, Durand, Eric Y., Mandon, Emeline, Estadieu, Claire, Romanet, Vincent, Wiesmann, Marion, Tiedt, Ralph, Lehar, Joseph, de Weck, Antoine et al. · 2017 · Proceedings of the National Academy of Sciences
56. Targeting BCL-2 in B-cell lymphomas
    Matthew Steven Davids · 2017 · Blood
57. Biology and therapeutic targeting of molecular mechanisms in MPNs
    Joan How, Jacqueline Suen Garcia, Ann Mullally · 2022 · Blood
58. NF-κB: A Druggable Target in Acute Myeloid Leukemia
    Barbara Di Francesco, Daniela Verzella, Daria Capece, Davide Vecchiotti, Mauro Di Vito Nolfi, Irene Flati, Jessica Cornice, Monica Di Padova, Adriano Angelucci, Edoardo Alesse et al. · 2022 · Cancers
59. Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies
    Roula Khalil, Mona Diab‐Assaf, Jean-Marc Lemaı̂tre · 2023 · Cells
60. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
    Niki Karachaliou, Jordi Codony‐Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony, Ana A. Giménez-Capitán, Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, R. Gervais et al. · 2015 · Scientific Reports
61. How to unleash mitochondrial apoptotic blockades to kill cancers?
    Jing Deng · 2016 · Acta Pharmaceutica Sinica B
62. Therapeutics targeting Bcl-2 in hematological malignancies
    Astrid A. Ruefli-Brasse, John C. Reed · 2017 · Biochemical Journal
63. Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies
    Andrew E. Place, Kelly C. Goldsmith, Jean‐Pierre Bourquin, Mignon L. Loh, Lia Gore, Daniel A. Morgenstern, Yeshwant D. Sanzgiri, David Hoffman, Ying Yin Zhou, Jeremy A. Ross et al. · 2018 · Future Oncology
64. Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition
    Masum Rahman, Ian Olson, Moustafa A. Mansour, Lucas P. Carlstrom, Rujapope Sutiwisesak, Rehan Saber, Karishma R. Rajani, Arthur E. Warrington, Adam Howard, Mark A. Schroeder et al. · 2022 · Molecular Cancer Research
65. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kevin Jay Freise, Aksana K. Jones, Doerthe Eckert, Sven Mensing, Shekman L. Wong, Rod A. Humerickhouse, Walid M. Awni, Ahmed Hamed Salem · 2016 · Clinical Pharmacokinetics
66. Mito-priming as a method to engineer Bcl-2 addiction
    Jonathan Lopez, Margaux Bessou, Joel S. Riley, Evangelos Giampazolias, Franziska Todt, Tony Rochegüe, Andrew Oberst, Douglas R. Green, Frank Edlich, Gabriel Ichim et al. · 2016 · Nature Communications
67. The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2
    Zhimei Li, Yiyuan Zhang, Lixia Chen, Hua Li · 2018 · Food & Function
68. Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
    Yvonne de Jong, David Monderer, Emeline Brandinelli, Morgane Monchanin, Brendy E. van den Akker, Jolieke G. van Oosterwijk, Jean‐Yves Blay, Aurélie Dutour, Judith V.M.G. Bovée · 2018 · Oncogenesis
69. A BCL-xL/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice
    Yang Yang, Natacha Jn‐Simon, Yonghan He, Chunbao Sun, Peiyi Zhang, Wanyi Hu, Tian Tian, Huadong Zeng, Sreenivasulu Basha, Araceli S. Huerta et al. · 2025 · Nature Aging
70. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity
    Nicolas Malaquin, Arthur Vancayseele, Sophie Gilbert, Laureen Antenor-Habazac, Marc‐Alexandre Olivier, Zakia Ait Ali Brahem, Fred Saad C, Guila Delouya, Françis Rodier · 2020 · Cells
71. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis
    Sarah Kehr, Tinka Haydn, Annika Bierbrauer, Barnabas Irmer, Meike Vogler, Simone Fulda · 2020 · Cancer Letters
72. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy
    Valerie J. Carpenter, Tareq Saleh, So Min Lee, Graeme F. Murray, Jason C Reed, Andrew James Souers, Anthony C. Faber, Hisashi Harada, David A. Gewirtz · 2021 · Biochemical Pharmacology
73. 2-Aminobenzothiazoles in anticancer drug design and discovery
    G. Huang, Tomasz Cierpicki, Jolanta E. Grembecka · 2023 · Bioorganic Chemistry
74. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
    Ryan H. Kolb, Umasankar De, Sajid Ullah Khan, Yuewan Luo, Myung‐Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang et al. · 2021 · Nature Communications
75. The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer
    Ethan L. Morgan, Molly R. Patterson, Diego Barba‐Moreno, James A. Scarth, Adam Wilson, Andrew Macdonald · 2021 · Oncogene
76. Targeted Therapy Development in Acute Myeloid Leukemia
    Tulasigeri M. Totiger, Anirban Ghoshal, Jenna Zabroski, Anya K. Sondhi, Saanvi Bucha, Jacob Jahn, Yangbo Feng, Justin Taylor · 2023 · Biomedicines
77. Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease
    Weifeng He, Lingfeng Yan, Dongxue Hu, Jianlei Hao, Yih‐Cherng Liou, Gaoxing Luo · 2025 · MedComm
78. ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types
    Anderly C. Chüeh, Janson W.T. Tse, Michael John Dickinson, Paul Ioannidis, Laura J. Jenkins, Lars Tögel, BeeShin Tan, Ian Y. Luk, Mercedes Dávalos-Salas, Rebecca Nightingale et al. · 2017 · Clinical Cancer Research
79. <i>PIK3CA</i> mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
    Anderson, Gray R., Wardell, Suzanne E., Cakir, Merve, Crawford, Lorin, Leeds, Jim C., Nussbaum, Daniel P., Shankar, Pallavi S., Soderquist, Ryan S., Stein, Elizabeth M., Tingley, Jennifer P. et al. · 2016 · Science Translational Medicine
80. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors
    Darren C. Phillips, F. Gregory Buchanan, Dong Cheng, Larry R. Solomon, Xiao Hong Yu, John Xue, Stephen K. Tahir, Morey L. Smith, Haichao Zhang, Deborah L. Widomski et al. · 2021 · Cancer Research
81. Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer
    Daniel Westaby, Juan M. Jiménez‐Vacas, Ana Padilha, Andreas S. Varkaris, Steven P. Balk, Johann Sebastian De Bono, Adam Sharp · 2021 · Cancers
82. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells
    Diane Moujalled, Adam G. Southon, Eiman Saleh, Kerstin Brinkmann, Francine Ke, Melinda Iliopoulos, Ryan Stanley Cross, Misty Rayna Jenkins, Duong Nhu, Zilu Wang et al. · 2022 · Cell Death and Differentiation
83. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
    Yuxuan Liu, Patrizia Mondello, Tatiana Erazo, Neeta Bala Tannan, Zahra Asgari, Elisa de Stanchina, Gouri J. Nanjangud, Venkatraman Seshan, Shenqiu Wang, Hans‐Guido Wendel et al. · 2018 · Proceedings of the National Academy of Sciences
84. Aging and Mesenchymal Stem Cells: Therapeutic Opportunities and Challenges in the Older Group
    Huan Chen, Ousheng Liu, Sijia Chen, Yueying Zhou · 2021 · Gerontology
85. Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
    Hanjie Yi, Miao‐Zhen Qiu, Luping Yuan, Qiuyun Luo, Wentao Pan, Suna Zhou, Lin Zhang, Xianglei Yan, Dajun Yang · 2020 · Cancer Medicine
86. 1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design
    Faheem Faheem, Banoth Karan Kumar, Kondapalli Venkata Gowri Chandra Sekhar, Subhash Chander, Selvaraj Kunjiappan, Sankaranarayanan Murugesan · 2021 · Expert Opinion on Drug Discovery
87. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
    Thomas Eliot Lew, John Francis Seymour · 2022 · Journal of Hematology & Oncology
88. The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia
    Gilad Itchaki, Jennifer R. Brown · 2016 · Therapeutic Advances in Hematology
89. Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor
    Yi‐Yin Ku, Vincent S. Chan, Alan C. Christesen, Timothy Grieme, Mathew M. Mulhern, Yu‐Ming Pu, Michael D. Wendt · 2019 · The Journal of Organic Chemistry
90. Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
    Julie Lafontaine, Guillaume B. Cardin, Nicolas Malaquin, Jean-Sébastien Boisvert, Françis Rodier, Philip Wong · 2021 · Cancers
91. Massively parallel assessment of human variants with base editor screens
    Hanna, Ruth E, Hegde, Mudra, Fagre, Christian R, DeWeirdt, Peter C, Sangree, Annabel K, Szegletes, Zsofia, Griffith, Audrey, Feeley, Marissa N, Sanson, Kendall R, Baidi, Yossef et al. · 2020
92. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
    Stover, Elizabeth H., Baco, Maria B., Cohen, Ofir, Li, Yvonne Y., Christie, Elizabeth L., Bagul, Mukta, Goodale, Amy, Lee, Yenarae, Pantel, Sasha, Rees, Matthew G. et al. · 2019 · Molecular Cancer Research
93. Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology
    Balak Das Kurmi, Preeti Patel, Rishi Paliwal, Shivani Rai Paliwal · 2020 · Journal of Drug Delivery Science and Technology
94. Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment
    Zhenwei Zhang, Lijun Bai, Linghui Hou, Hongguang Deng, Shenglin Luan, Dan Liu, Min Huang, Linxiang Zhao · 2022 · European Journal of Medicinal Chemistry
95. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice
    N. Anstee, R. Bilardi, Ashley P Ng, Zhen Xu, M. Robati, C. Vandenberg, S. Cory · 2018 · Cell Death and Differentiation
96. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
    Zhichuan Zhu, Jiwei Liu, Can Yang, Miao Zhao, Zhi‐Qi Xiong · 2019 · Cell Death and Disease
97. Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma
    Victoria M. Smith, Anna Dietz, Kristina Henz, Daniela Brücher, Ross A. Jackson, Lisa Kowald, Sjoerd J. L. van Wijk, Sandrine Jayne, Salvador Macip, Simone Fulda et al. · 2019 · Haematologica
98. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
    Siti Fairus Abdul Rahman, Kalaivani Muniandy, Yong Kit Soo, Elvin Yu Huai Tiew, Ke Xin Tan, Timothy Edward Bates, Nethia Mohana‐Kumaran · 2020 · Biochemistry and Biophysics Reports
99. Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins
    Daria R. Bulanova, Aleksandr Ianevski, Andrii Bugai, Yevhen A. Akimov, Suvi H. Kuivanen, Henrik Paavilainen, Laura Kakkola, Jatin Nandania, Laura Turunen, Tiina Öhman et al. · 2017 · Viruses
100. Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling
     Tamara Vervloessem, Martijn Kerkhofs, Rita Maria Laura La Rovere, Flore Sneyers, Jan B. Parys, Geert Bultynck · 2017 · Cell Calcium